HLS Therapeutics Inc. (HLS) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Hls Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:01.465 -- 00:00:07.114 Good morning and welcome to the Q1 2025 Financial Results Conference call 00:00:07.114 -- 00:00:12.121 for HLS Therapeutics. At this point, I would like to turn the call over to 00:00:12.121 -- 00:00:16.207 David Mason, Investor Relations, for the introductory remarks. 00:00:16.207 -- 00:00:18.908 Please go ahead, sir. 00:00:18.972 -- 00:00:22.217 Good morning, everyone, and thank you for joining us today. 00:00:22.217 -- 00:00:27.264 With me on today's call is Craig Millian, Chief Executive Officer, John 00:00:27.264 -- 00:00:32.860 Hanna, Chief Financial Officer, Brian Walsh, Chief Commercial Officer. 00:00:32.860 -- 00:00:37.246 Earlier this morning, we issued a news release announcing our financial results for the 00:00:37.246 -- 00:00:40.952 three months ended March 31st, 2025. 00:00:40.952 -- 00:00:45.979 This news release, along with our MD&A and financial statements, is available 00:00:45.979 -- 00:00:50.286 on HLS's website and on CDAR+. 00:00:50.286 -- 00:00:55.834 Please note that slides accompanying today's call can be viewed via the webcast, 00:00:55.834 -- 00:01:00.589 a link to which is available in our earnings press release and at our website on the 00:01:00.589 -- 00:01:02.652 events page. 00:01:02.652 -- 00:01:06.979 Certain matters discussed in today's conference call or answers that may be given to 00:01:06.979 -- 00:01:11.066 questions could constitute forward-looking statements. 00:01:11.066 -- 00:01:15.152 Actual results could differ materially from those anticipated. 00:01:15.152 -- 00:01:19.700 Risk factors that could affect results are detailed in the company's annual information 00:01:19.700 -- 00:01:23.302 form, which has been filed on CDAR+. 00:01:23.546 -- 00:01:28.282 During the call, we will refer t...